Compare · JNJ vs TEVA
JNJ vs TEVA
Side-by-side comparison of Johnson & Johnson (JNJ) and Teva Pharmaceutical Industries Limited (TEVA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both JNJ and TEVA operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- JNJ is the larger of the two at $560.33B, about 14.1x TEVA ($39.81B).
- Over the past year, JNJ is up 49.6% and TEVA is up 84.2% - TEVA leads by 34.6 points.
- TEVA has been more active in the news (30 items in the past 4 weeks vs 8 for JNJ).
- Both have 25 recent analyst ratings on file.
- Company
- Johnson & Johnson
- Teva Pharmaceutical Industries Limited
- Price
- $232.15-0.24%
- $33.26-2.69%
- Market cap
- $560.33B
- $39.81B
- 1M return
- +4.36%
- -7.62%
- 1Y return
- +49.56%
- +84.16%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NYSE
- IPO
- News (4w)
- 8
- 30
- Recent ratings
- 25
- 25
Johnson & Johnson
Johnson & Johnson researches and develops, manufactures, and sells a range of products in the health care field worldwide. It operates through three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; smoking cessation products under the NICORETTE brand; and acid reflux products under the PEPCID brand. This segment also provides women's health products, such as sanitary pads and tampons under the STAYFREE, CAREFREE, and o.b. brands; wound care products comprising adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. The Pharmaceutical segment offers products in various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. The Medical Devices segment provides electrophysiology products to treat cardiovascular diseases and neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. The company markets its products to general public, and retail outlets and distributors, as well as distributes directly to wholesalers, hospitals, and health care professionals for prescription use. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
Teva Pharmaceutical Industries Limited
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams. It also develops, manufactures, and sells active pharmaceutical ingredients. In addition, it focuses on the central nervous system, pain, respiratory, and oncology areas. Its products in the central nervous system and pain area include Copaxone for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine; and AUSTEDO for the treatment of tardive dyskinesia and chorea associated with Huntington disease. The company's products in the respiratory market comprise ProAir, QVAR, ProAir Digihaler, AirDuo Digihaler, and ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick for the treatment of asthma and chronic obstructive pulmonary disease. Its products in the oncology market include Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. The company was founded in 1901 and is based in Tel Aviv-Yafo, Israel.
Latest JNJ
- Johnson & Johnson to Acquire Firefly Bio, Inc. to Expand Oncology Pipeline with Novel Degrader Antibody Conjugate Platform
- Johnson & Johnson presents new data further reinforcing the role of nipocalimab in lowering the autoantibodies driving Sjögren's disease
- Johnson & Johnson's Phase 3 prostate cancer study shows ERLEADA® (apalutamide) before and after surgery significantly reduces risk of metastasis or death, breaking a decades-long treatment paradigm
- RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) demonstrates prolonged clinical benefit as a first-line treatment for atypical EGFR-mutated non-small cell lung cancer
- New TECVAYLI® (teclistamab-cqyv) data demonstrate superior progression-free and overall survival as early as first relapse in multiple myeloma
- FDA approves label expansion, cementing TREMFYA® as the only IL‑23 inhibitor proven to help stop further joint damage
- Johnson & Johnson to Host Investor Conference Call on Second-Quarter Results
- SEC Form SD filed by Johnson & Johnson
- SEC Form 13F-HR filed by Johnson & Johnson
- CNS Drug Delivery Technologies Are Reshaping Alzheimer's and Biodefense Research
Latest TEVA
- Director Barer Sol J converted options into 21,739 units of Ordinary Shares, increasing direct ownership by 5% to 448,011 units (SEC Form 4)
- Director Lichtenstein Chen converted options into 14,492 units of Ordinary Shares, increasing direct ownership by 302% to 19,296 units (SEC Form 4)
- Director Crane Rosemary A converted options into 14,492 units of Ordinary Shares, increasing direct ownership by 13% to 127,739 units (SEC Form 4)
- Director Elstein Amir converted options into 14,492 units of Ordinary Shares, increasing direct ownership by 0.69% to 2,118,455 units (SEC Form 4)
- Director Lieberman Gerald M converted options into 14,492 units of Ordinary Shares, increasing direct ownership by 13% to 130,149 units (SEC Form 4)
- Director Nisen Perry converted options into 14,492 units of Ordinary Shares, increasing direct ownership by 14% to 119,807 units (SEC Form 4)
- Director Satchi-Fainaro Ronit converted options into 14,492 units of Ordinary Shares, increasing direct ownership by 15% to 112,401 units (SEC Form 4)
- Director Zaks Tal Zvi converted options into 14,492 units of Ordinary Shares, increasing direct ownership by 25% to 73,264 units (SEC Form 4)
- Director Mignone Roberto converted options into 14,492 units of Ordinary Shares, increasing direct ownership by 14% to 119,807 units (SEC Form 4)
- President and CEO Francis Richard D converted options into 13,043 units of Ordinary Shares and sold $211,356 worth of Ordinary Shares (6,153 units at $34.35) as part of a pre-agreed trading plan, increasing direct ownership by 0.59% to 1,177,529 units (SEC Form 4) (tax liability)